Glioma Biology and Treatment Approaches

Gliomas constitute a heterogeneous group of primary brain tumours arising from glial cells, ranging from diffusely infiltrative low-grade lesions to the highly aggressive glioblastoma. Their molecular landscape is shaped by key genetic alterations—such as IDH mutation status, EGFR amplification and TERT promoter mutations—that drive tumour proliferation, invasion and angiogenesis. The blood–brain barrier and a subpopulation of therapy-resistant glioma stem cells together hinder effective drug delivery and contribute to recurrence. The tumour microenvironment, populated by diverse immune and stromal cells, creates an immunosuppressive niche that further limits conventional therapies. Current standard management combines maximal safe resection with radiotherapy and temozolomide chemotherapy, yet overall survival remains poor for high-grade disease. Emerging strategies focus on molecularly targeted agents, modulation of immune checkpoints, reprogramming of tumour-associated macrophages, normalisation of aberrant vasculature and exploitation of novel anatomic lymphoid sites. Advances in spatial and single-cell profiling are refining our understanding of cell-cell interactions, guiding the development of precision therapies tailored to each glioma’s unique biology.

Research from Nature Portfolio

High-dimensional spatial analysis has revealed unprecedented immune heterogeneity within high-grade gliomas, distinguishing cellular neighbourhoods linked to patient survival. Imaging mass cytometry of primary and metastatic brain tumours identified distinct macrophage and T-cell assemblies, including a myeloperoxidase-positive macrophage subset associated with longer survival, underscoring the importance of spatial context in anti-tumour immunity. Concurrently, work on cranioencephalic lymphoid units demonstrated that the bone marrow adjacent to glioblastoma hosts a reservoir of tumour-reactive CD8+ T cells. These cells display markers of activation and egress from the cranial niche, offering a potential avenue to harness endogenous immunity by preserving and stimulating these anatomically defined immune reservoirs.

Glioma Biology and Treatment Approaches publication trend

The graph below shows the total number of articles in glioma biology and treatment approaches across all publications each year (not limited to Nature Index journals).

Technical terms

Glioma: A tumour originating from glial cells in the central nervous system, varying in grade and aggressiveness.

Glioblastoma: The most aggressive and lethal form of diffuse glioma, characterised by rapid growth, necrosis and microvascular proliferation.

Blood–brain barrier (BBB): A selective endothelial barrier that regulates molecular and cellular passage between the bloodstream and the brain.

Glioma stem cells (GSCs): A subpopulation of tumour cells with self-renewal capacity that contribute to therapy resistance and recurrence.

Tumour microenvironment (TME): The complex milieu of non-malignant cells, extracellular matrix and signalling molecules surrounding tumour cells.

Tumour-associated macrophages (TAMs): Macrophages recruited to the TME that can adopt pro- or anti-tumour phenotypes under niche cues.

Hypoxia: A low-oxygen condition within tumours that influences cell signalling, metabolism and immune cell function.

Spatial profiling: Analytical methods that map molecular and cellular features within tissue sections to preserve anatomical context.

References

1. The tumor-enriched small molecule gambogic amide suppresses glioma by targeting WDR1-dependent cytoskeleton remodeling. Signal Transduction and Targeted Therapy (2023).
2. Single-cell spatial immune landscapes of primary and metastatic brain tumours. Nature (2023).
3. Cranioencephalic functional lymphoid units in glioblastoma. Nature Medicine (2024).
4. Identification of hypoxic macrophages in glioblastoma with therapeutic potential for vasculature normalization. Cancer Cell (2024).